Relation Between Viral Fitness and Immune Escape Within the Hepatitis C Virus Protease
Overview
Authors
Affiliations
Background: The hepatitis C virus (HCV) mutates within human leucocyte antigen (HLA) class I restricted immunodominant epitopes of the non-structural (NS) 3/4A protease to escape cytotoxic T lymphocyte (CTL) recognition and promote viral persistence. However, variability is not unlimited, and sometimes almost absent, and factors that restrict viral variability have not been defined experimentally.
Aims: We wished to explore whether the variability of the immunodominant CTL epitope at residues 1073-1081 of the NS3 protease was limited by viral fitness.
Patients: Venous blood was obtained from six patients (four HLA-A2+) with chronic HCV infection and from one HLA-A2+ patient with acute HCV infection.
Methods: NS3/4A genes were amplified from serum, cloned in a eukaryotic expression plasmid, sequenced, and expressed. CTL recognition of naturally occurring and artificially introduced escape mutations in HLA-A2-restricted NS3 epitopes were determined using CTLs from human blood and genetically immunised HLA-A2-transgenic mice. HCV replicons were used to test the effect of escape mutations on HCV protease activity and RNA replication.
Results: Sequence analysis of NS3/4A confirmed low genetic variability. The major viral species had functional proteases with 1073-1081 epitopes that were generally recognised by cross reactive human and murine HLA-A2 restricted CTLs. Introduction of mutations at five positions of the 1073-1081 epitope prevented CTL recognition but three of these reduced protease activity and RNA replication.
Conclusions: Viral fitness can indeed limit the variability of HCV within immunological epitopes. This helps to explain why certain immunological escape variants never appear as a major viral species in infected humans.
Machraoui S, Errafii K, Oujamaa I, Belghali M, Hakmaoui A, Lamjadli S Diseases. 2024; 12(5).
PMID: 38785761 PMC: 11120154. DOI: 10.3390/diseases12050106.
Osuch S, Laskus T, Perlejewski K, Berak H, Bukowska-Osko I, Pollak A Front Immunol. 2022; 13:832206.
PMID: 35386708 PMC: 8977521. DOI: 10.3389/fimmu.2022.832206.
Adaptive Immune Responses, Immune Escape and Immune-Mediated Pathogenesis during HDV Infection.
Oberhardt V, Hofmann M, Thimme R, Neumann-Haefelin C Viruses. 2022; 14(2).
PMID: 35215790 PMC: 8880046. DOI: 10.3390/v14020198.
In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?.
Echeverria N, Comas V, Aldunate F, Perbolianachis P, Moreno P, Cristina J World J Hepatol. 2021; 13(10):1234-1268.
PMID: 34786164 PMC: 8568586. DOI: 10.4254/wjh.v13.i10.1234.
Mazouz S, Boisvert M, Abdel-Hakeem M, Khedr O, Bruneau J, Shoukry N J Immunol. 2021; 207(4):1180-1193.
PMID: 34341170 PMC: 8434894. DOI: 10.4049/jimmunol.2001386.